TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05154084

Intervention type: BEHAVIORAL
Intervention: Performance feedback and education
Description: Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
Study: NCT05887102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACHA Program
Description: Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
Study: NCT06565884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home radiofrequency skin treatment instrument
Description: Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
Study: NCT05184517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oph1
Description: 0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oph1
Description: 0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restasis
Description: 0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restasis
Description: 0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
Study: NCT06565884

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic coupler for medical purposes
Description: In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
Study: NCT05229783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electronic chromoendoscopy
Description: Inspection of the Barrett's esophagus using the electronic chromoendoscopy modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions.
Study: NCT05339022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo exercise intervention
Study: NCT05229783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White light endoscopy with Seattle protocol
Description: Inspection of the Barrett's esophagus using the white light modality of the endoscope for the detection of high-grade dysplasia and adenocarcinoma lesions, and then systemic quadrantic biopsies every 2 centimeters from the esogastric junction to the top of the Barett's esophagus (Seattle protocol)
Study: NCT05339022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Relaxation Therapy
Description: Undergo progressive muscles relaxation exercises
Study: NCT05499377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
Study: NCT04581226

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
Study: NCT06130241

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sentinle lymphnode biopsy
Description: intraoperative sentinle lymphnode biopsy
Study: NCT05277376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemotrizinol (6%)
Description: Active sunscreen ingredient (Broad spectrum UV-Filter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemotrizinol (6%)
Description: Active sunscreen ingredient (Broad spectrum UV-Filter)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemotrizinol (6%)
Description: Active sunscreen ingredient (Broad spectrum UV-Filter)
Study: NCT06462924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeepGad
Description: Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
Study: NCT05811624

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.
Description: 14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful.
Study: NCT06319326

Intervention type: OTHER
Intervention: Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.
Description: This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
Study: NCT04680390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care engagement practices
Description: The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
Study: NCT06271434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: THYROX (Atlantic krill oil
Description: The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The control capsules will be made of olive oil of equal size and color.
Study: NCT06316349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Resistance Training Program
Description: The hip range of motion (ROM) will be fixed at 45 degrees due to the limitation imposed by the femoral insertion of the intra-aortic balloon pump in both lower limbs to allow for a 45-degree knee extension ROM. Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets. The intensity (resistive load) will be set at 60% of the baseline load, calculated using the one-repetition maximum (1RM) test and increased by 10% after every 5 interventions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: For NMES, two electrodes (area of 5 x 9 cm) will be positioned perpendicular to the muscles of the femoral quadriceps. The parameters of NMES will remain fixed throughout the study: pulsed, biphasic current, with a frequency of 35Hz, pulse width of 1000µs, on-time of 7 seconds (with 3 seconds of rise, 1 second of sustainment, and 3 seconds of descent), and off-time switched off. These settings allow the onset of NMES to be synchronous with the start and end of hip extension for simultaneous execution with resistance exercises and a total of 40 stimulations. The intensity will be gradually adjusted until evoked contractions of grade 4 to 5 (partial muscle recruitment and total muscle recruitment) or the maximum intensity tolerated by the patient is achieved.
Study: NCT04680390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women
Description: kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
Study: NCT06208670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises
Description: PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
Study: NCT06217848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda
Description: Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
Study: NCT06166381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Antibacterial Agents
Description: Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Antibacterial Agents
Description: Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft
Description: in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
Study: NCT05144100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with or without Neck Dissection
Description: An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
Study: NCT05144100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin based chemotherpay
Description: Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
Study: NCT06208670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Violent tendency Scale
Description: Violent tendency Scale
Study: NCT05568628

Intervention type: DEVICE
Intervention: ultrasound
Description: screening of breast lesions by ultrasonography

Intervention type: DEVICE
Intervention: ultrasound
Description: screening of breast lesions by ultrasonography
Study: NCT05327517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
Study: NCT04724408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VieScope
Description: see above

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: see above
Study: NCT05032482

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.
Study: NCT05327517

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
Study: NCT05770817

Intervention type: OTHER
Intervention: N/A: SKyRoCKeT is an observational study
Description: None; this is an observational study
Study: NCT06524128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dreeft wheels (EPPUR company)
Description: The braking system (Dreeft wheels) is installed directly on the participant's wheelchair, by a trained occupational therapist. The Dreeft wheels are supplied for a period of 1 month.
Study: NCT05569239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 480µg
Description: One single administration intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: One single administration intramuscularly at Day 1.
Study: NCT05917613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)
Description: Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
Study: NCT05335876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onasemnogene abeparvovec
Description: Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Study: NCT06458543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Longidaza
Description: Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 500 mg
Description: Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
Study: NCT05701293

Intervention type: PROCEDURE
Intervention: Endovascular implantation of Renzan Stent
Description: Endovascular treatment of LEAD patients with Renzan Stent
Study: NCT04534686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogXergaming
Description: The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matter of Balance Training
Description: The program emphasizes practical coping strategies that include group discussions, mutual problem solving, exercises to improve strength, coordination and balance, and, a home safety evaluation.
Study: NCT05326711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based motor imagery training
Description: Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.
Study: NCT05557344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV
Description: An IV infusion of 15mg/kg of acetaminophen (PrACETAMINOPHEN INJECTION, AVIR Pharma Inc.) (maximum single dose:1g) will be administered regularly every 6h as a 15-minute intravenous infusion. At the same time, an oral placebo with similar appearance as the corresponding acetaminophen oral solution will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: A liquid oral acetaminophen suspension will be administered regularly every 6h at a dose of 15mg/kg (maximum single dose: 1g). An IV infusion of NaCl 0.9% corresponding to the volume of IV acetaminophen will be administered as a 15-minute intravenous infusion at the same time as the oral dose. PrACETAMINOPHEN INJECTION ® is a clear and colorless liquid undistinguishable from NaCl 0.9%.
Study: NCT05726578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung recruitment
Description: establishment of lung recruitment using high frequency ventilation and assessment with chest ultrasound and echocardiography
Study: NCT04566328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab and Hyaluronidase-fihj
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies